US 11,931,464 B2
Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
Rosaleen McLaughlin, Swindon (GB); Simon Andrew Martyn Howes, Swindon (GB); Craig Wheadon, Swindon (GB); Jonathon Whitehouse, Herne Bay (GB); and Adam Parker, Swindon (GB)
Assigned to Catalent U.K. Swindon Zydis Limited, Swindon (GB)
Filed by Catalent U.K. Swindon Zydis Limited, Glasgow (GB)
Filed on Jul. 28, 2021, as Appl. No. 17/387,803.
Application 17/387,803 is a continuation of application No. 17/008,108, filed on Aug. 31, 2020, granted, now 11,077,067.
Application 17/008,108 is a continuation of application No. 16/798,130, filed on Feb. 21, 2020, granted, now 11,166,919.
Claims priority of provisional application 62/809,293, filed on Feb. 22, 2019.
Claims priority of provisional application 62/809,287, filed on Feb. 22, 2019.
Claims priority of provisional application 62/809,307, filed on Feb. 22, 2019.
Prior Publication US 2021/0353551 A1, Nov. 18, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/50 (2006.01); A61K 31/192 (2006.01); A61K 47/00 (2006.01); A61K 47/26 (2006.01); A61K 47/36 (2006.01); A61K 47/42 (2017.01)
CPC A61K 9/5073 (2013.01) [A61K 9/501 (2013.01); A61K 9/5015 (2013.01); A61K 9/5089 (2013.01); A61K 31/192 (2013.01); A61K 47/26 (2013.01); A61K 47/36 (2013.01); A61K 47/42 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A coated active pharmaceutical ingredient (“API”) consisting of:
a wax surrounding an API; and
a silica partially embedded in and/or embedded in the wax, wherein the silica produces a slower dissolution profile for the API as compared to API without silica.